Ragon Institute of Mass General, MIT, and Harvard
Tariro Makadzange is the CEO and Founder of Charles River Medical Group, a position held since September 2021. An Associate Member at the Ragon Institute of MGH, MIT, and Harvard since July 2015, Tariro previously worked at Gilead Sciences in various leadership roles, including Senior Director of Biology and External Innovation from August 2020 to September 2021, and Director of Biology from November 2018 to March 2020. With a strong foundation in academia, Tariro held several positions at Massachusetts General Hospital from July 2010 to December 2016, including Faculty in the Division of Infectious Diseases and Instructor of Medicine at Harvard Medical School. Tariro's medical training includes an M.D. from Harvard Medical School, complemented by a Ph.D. in Immunology from the University of Oxford and a Bachelor's Degree in Biochemistry from Smith College.
This person is not in any teams
This person is not in any offices
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.